Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Compounded semaglutide contains the same active ingredient as brand-name products, so the fundamental GI effects are the same
Clostridium butyricum - produces the postbiotic butyrate which stimulates GLP-1
After 68 weeks on semaglutide 2.4 mg weekly, participants lost an average of 14.9% of their body weight versus 2.4% on placebo
What Makes Semaglutide Different Uses a single hormone pathway (GLP-1) to support appetite control Often a great option for patients who prefer a more gradual approach Well-studied with a long track record in metabolic care What Makes Tirzepatide Different Activates two hormone pathways (GLP-1 and GIP) for broader metabolic support May provide stronger appetite suppression for some patients Often considered for patients who need additional metabolic support or have experienced plateaus What Clinical Trials Show GLP-1s Can Do The Proof in the Data Semaglutide By week 68, 86.4% lost at least 5%, 69.1% lost at least 10%, and 50.5% lost at least 15%
